We used the RC‐ODC/AZ system to “knockdown” the exogenous or endogenous KRAS oncoprotein at the post‐translational level in human HEK293T cells and the pancreatic cancer cell line PANC‐1, and our data imply the tractability of KRAS as a target degraded by the ODC/AZ pathway through the 26S proteasome without ubiquitination. The gene discussed is KRAS; the disease is familial pancreatic carcinoma.